The global Vulvovaginal Candidiasis Treatment Market is currently valued at USD 1035 million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in the healthcare sector the market is likely to propel to USD1607 Million by 2033.
The rapid increase and unrestrained usage of antibiotics leading to the high prevalence of yeast infection and increasing prevalence of VVC disorder are likely to drive the growth of the vulvovaginal candidiasis market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1035 Million |
| Projected Forecast Value (2033) | USD 1607 Million |
| Global Growth Rate (2023 to 2033) | 4.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider FMI, the vulvovaginal candidiasis industry grew at a CAGR of 4.3% from 2018 to 2022.
Vaginal yeast infection is a common fungal infection and is called candidal vaginitis or candidal vulvovaginitis Symptoms of vaginal yeast infection include itching, burning sensation or pain during urination or sexual intercourse, swelling, rashes, and redness.
Candida albicans are the most prevalent cause of fungal infections in people. Candida species are the most common cause of fungal urinary tract infections (UTIs). Candida UTIs can occur in the lower portion of the urinary tract or in some cases can ascend up to the kidneys.
The antifungal drug fluconazole can be used in many cases. VVC prevalence has increased due to growing diabetes cases and repeated antibiotic usage among individuals.
The market is expected to grow due to an increase in Research and Development initiatives for precise diagnosis. Various government and non-government bodies, including the World Health Organization and the European Institute of Women's Health (EIWH), have launched public awareness campaigns about women's health.
Demand for the VVC treatment market is expected to expand at a CAGR of 4.5% from 2023 to 2033, with the global market predicted to reach a valuation of USD 1607 Million by 2033.
The growing prevalence of vulvovaginal candidiasis infection is further driving the demand for new therapeutics for treatment, augmenting the growth of the market
The increasing prevalence of vulvovaginal candidiasis infection is the primary factor driving the market growth. For instance, vulvovaginal candidiasis affects about 138 million women annually (range 103 to 172 million), with a global annual prevalence of 3871 per 100 000 women; 372 million women are affected by recurrent vulvovaginal candidiasis over their lifetime. In addition, recurrent VVC prevalence is rising, affecting more than 9% of women annually.
The high growth rate can be attributed to the rising disease burden of VVC and increasing testing rates. Positive changes, such as healthcare benefits by the government, increased awareness among consumers, and willingness to avail medical treatments are also expected to drive the growth of the vulvovaginal candidiasis treatment market.
Also, an increase in healthcare spending and the growth of healthcare infrastructure are also driving the global acute vulvovaginal candidiasis treatment market.
Increased Incidence of Vaginal Infections and Rising Research and development activities & Public Awareness about Women's Health
Vaginal yeast infection is a common fungal infection and is called candidal vaginitis or candidal vulvovaginitis (CVV)
An increase in the global burden of various ailments such as cardiovascular, neurological, and gastrointestinal diseases as well as cancer has boosted the consumption of broad-spectrum antibiotics, thereby propelling the number of yeast infection cases.
The rapid increase in the global disease burden, coupled with escalating demand for better treatment options and an increasing number of hospital-acquired infections, is also propelling the demand for bacterial vulvovaginal candidiasis treatment.
Furthermore, expanding healthcare infrastructure in developing economies, availability of pharmaceutical drugs, and robust technological advancements in the biopharmaceutical industries are all contributing to significant opportunities for vulvovaginal candidiasis treatment over the forecasted period.
Principal Consultant
Lack of Awareness of Vulvovaginal Candidiasis Treatment
Although the vulvovaginal candidiasis treatment market has numerous end-uses, there are some obstacles that likely pose a challenge to market growth during the forecasting.
The lack of awareness among people in developing countries may restrain the market growth. Also, the lack of experience in using advanced technology and the high cost associated with the diagnosis and treatment procedure is expected to act as a restraint to the market.
Developed Healthcare Facilities, High Incidence of Diseases, and Presence of Key Producers in the North America Market
The North American vulvovaginal candidiasis treatment market is expected to account for the highest market share of around 39.2% in the global landscape in 2023.
The region is expected to expand further at a steady growth rate maintaining its dominant position throughout the forecast period. This dominance can be attributed to the rise in patient awareness and increased healthcare expenditure in the region.
A recent Harvard study showed that there are approximately 6 Million American women who are suffering from vulvodynia. This region's established healthcare infrastructures, as well as the high frequency of disease and the presence of important manufacturers, are major factors contributing towards vulvovaginal candidiasis treatment market share.
Product approvals and launches for treatment of vulvovaginal candidiasis treatment to boost the growth of the vulvovaginal candidiasis treatment market in North America.
For instance, In June 2021, Scynexis, Inc. announced the FDA approval for their novel drug BREXAFEMME indicated for VVC treatment. All these launches are anticipated to fuel the industry's growth in the region.
Well-established Healthcare Infra in Europe Driving Vulvovaginal Candidiasis Treatment
Europe is one of the top regions driving vulvovaginal candidiasis treatment demand. The country's prospects are being boosted by the presence of a well-developed healthcare infrastructure and the availability of skilled medical staff.
Advanced therapeutic options, new approvals, launches, and proactive government measures further contribute to regional vulvovaginal candidiasis treatment market growth.
Throughout the projected period, Europe’s market is expected to grow at a robust rate. The country is boosting its spending on biopharmaceutical research and development in order to develop cures for uncommon diseases, which bodes well for vulvovaginal candidiasis treatment system providers in the region. The market in Europe is expanding rapidly, due to an increase in the patient population, especially in the United Kingdom and Germany.
Rising Awareness of Vaginal Disorders & Availability of Advanced Treatment Aiding Sales of Vulvovaginal Candidiasis Treatment Market
During the projection period, the Asia Pacific vulvovaginal candidiasis treatment market is predicted to develop at the fastest rate. This is due to a significant number of unmet clinical requirements, improved knowledge of early diagnosis, and the availability of effective medications.
Developing economies such as China and Japan are projected to contribute to the expansion of the market in the Asia Pacific due to better healthcare infrastructure, economic growth, an increase in the number of insurance payers, an expansion of the private healthcare sector, and an increase in education and awareness.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| United Kingdom | 4.3% |
|---|---|
| India | 4.3% |
| South Korea | 4.1% |
| China | 4.2 % |
| USA | 4.4 % |
The oral segment generates high revenue in the vulvovaginal candidiasis treatment market
The oral segment dominated the industry in 2022 and accounted for the maximum share of more than 43.2 % of the total revenue. It is anticipated to maintain its share throughout the forecast period owing to the common & convenient route of administration for azoles, good bioavailability, and use for anti-fungal drugs.
Oral fluconazole is the most common prescription drug recommended as treatment and maintenance therapy. It is also effective as short-duration therapy in recurrent VVC cases. Recently, the FDA has approved two oral dosage regimes of VIVJOA (oteseconazole) to reduce incidences of recurrent VVC. The topical segment is expected to grow at a steady CAGR during the study period.
Also, the presence of other topical products such as over-the-counter and prescription formulations boosts the demand in the market. According to IDSA guidelines, uncomplicated VVC should be treated with topical antifungal agents. Furthermore, oral azoles are ineffective in treating. Glabrata vulvovaginitis, thereby, is prescribed for topical intravaginal boric acid or topical flucytosine cream.
Hospital Pharmacy Segment remains Dominant among other types
In terms of distribution channels, the global vulvovaginal candidiasis treatment market can be categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.
The hospital pharmacy segment is projected to account for a major share of the global vulvovaginal candidiasis treatment market by 2033 as a large number of patients treated in hospitals
On the other hand, the online pharmacy distribution channel segment is also expected to grow at a significant CAGR during the forecast period. The preference for online purchasing is high due to the convenience and other benefits, such as home delivery.
Amid the pandemic, people experienced the comfort of delivery services and reduced travel time for prescription filling retail stores. The COVID-19 pandemic boosted the online segment due to the government restrictions like nationwide lockdowns and stay-at-home orders to curb the spread of the virus.
Viamet Pharmaceuticals, and Cidara Therapeutics, are some of the start-ups in the vulvovaginal candidiasis treatment market
Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., Pfizer, Inc., Cadila Pharmaceuticals, Bayer AG., Bristol-Myers Squibb Company are some of the key companies in the vulvovaginal candidiasis treatment market.
These players are continuously adopting various strategies such as new product launches, facility expansions, mergers, collaborations, partnerships, and acquisitions to increase their revenue share and gain a competitive edge in the market. for instance,
In October 2022 - Astellas Pharma Inc. and Pantherna Therapeutics GmbH announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation)*.
In August 2022 – Mycovia Pharmaceuticals, Inc. announced that it will present VIVJOA™ (oteseconazole) capsules in patients with recurrent vulvovaginal candidiasis (RVVC) at the 2022 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. VIVJOA is the first and only FDA-approved medication for RVVC indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential
In July 2022 – Mycovia Pharmaceuticals, Inc. announced the USA availability of VIVJOA™ (oteseconazole) capsules, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
In September 2021 - Basilea Pharmaceutica Ltd. and its partner Asahi Kasei Pharma Corporation filed a New Drug Application (NDA) for the marketing authorization of isavuconazole in Japan for the treatment of the fungal infections aspergillosis, mucormycosis and cryptococcosis.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR from 2023 to 2033 |
| Expected Market Value (2023) | USD 1035 Million |
| ProjectedForecast Value (2033) | USD 1607 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Route of administration, Distribution Channel, Regions |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa(MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Malaysia, Thailand, India, Singapore, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Astellas Pharma Inc.; Mycovia Pharmaceuticals, Inc.; Basilea Pharmaceutica Ltd.; Scynexis, Inc.; Grupo Ferrer Internacional S.A.; Pfizer, Inc.; Cadila Pharmaceuticals; Bayer AG.; Bristol-Myers Squibb Company |
| Customization | Available Upon Request |
The global vulvovaginal candidiasis treatment market is likely to reach a valuation of USD 1035 million by the end of 2023.
Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutical Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., and Pfizer are some of the key players in the global vulvovaginal candidiasis treatment market
Sales of the vulvovaginal candidiasis treatment market are likely to expand at 4.5% CAGR through 2033.
The USA, Canada, Japan, China, and Germany are expected to drive most of the demand for the vulvovaginal candidiasis treatment market.
By the end of 2033, the global market for vulvovaginal candidiasis treatment market is predicted to reach a valuation of USD 1607 Million
1. Executive Summary | Vulvovaginal Candidiasis Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Class 5.1. Clotrimazole 5.2. Nystatin 5.3. Fluconazole 5.4. Ketoconazole 5.5. Terbinafine 5.6. Terconazole 5.7. Others 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Route of Administration 6.1. Oral 6.2. Intravenous 6.3. Topical 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 7.1. Hospital Pharmacy 7.2. Retail Pharmacy 7.3. Online Pharmacy 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. Middle East and Africa (MEA) 9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Astellas Pharma Inc. 18.2. Mycovia Pharmaceuticals, Inc. 18.3. Basilea Pharmaceutica Ltd. 18.4. Scynexis, Inc. 18.5. Grupo Ferrer Internacional S.A. 18.6. Pfizer, Inc. 18.7. Cadila Pharmaceuticals 18.8. Bayer AG 18.9. Bristol-Myers Squibb Company 18.10. Pacgen Life Science Corporation 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Vulvovaginal Candidiasis Treatment Market
